← 返回

白细胞介素 15 在细胞免疫治疗癌症中的应用

英文原题:Interleukin 15 in Cell-Based Cancer Immunotherapy.

查看英文原题

Interleukin 15 in Cell-Based Cancer Immunotherapy.

PubMed 2022/06/30(内容时间) Int J Mol Sci Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

基于细胞的癌症免疫疗法,如嵌合抗原受体(CAR)工程化T细胞和自然杀伤(NK)细胞疗法,已成为癌症治疗的一项革命性新支柱。白细胞介素15(IL-15)是一种强效免疫刺激性细胞因子,可增强T和NK细胞免疫应答;其可靠性和效力显示有望提高现有细胞疗法的治疗效果。IL-15在结构上与白细胞介素2(IL-2)相似,可支持CD8+记忆T细胞持续存在,同时抑制IL-2诱导的T细胞死亡,从而更好地维持长期抗肿瘤免疫。本文综述IL-15生物学、IL-15和/或其衍生物作为免疫治疗药物给药的研究,以及过继细胞治疗中经IL-15强化的免疫细胞。还讨论将IL-15纳入细胞免疫治疗的优势和挑战,并提出未来研究方向。

展开英文摘要原文

Cell-based cancer immunotherapy, such as chimeric antigen receptor (CAR) engineered T and natural killer (NK) cell therapies, has become a revolutionary new pillar in cancer treatment. Interleukin 15 (IL-15), a potent immunostimulatory cytokine that potentiates T and NK cell immune responses, has demonstrated the reliability and potency to potentially improve the therapeutic efficacy of current cell therapy.

Structurally similar to interleukin 2 (IL-2), IL-15 supports the persistence of CD8 + memory T cells while inhibiting IL-2-induced T cell death that better maintains long-term anti-tumor immunity. In this review, we describe the biology of IL-15, studies on administrating IL-15 and/or its derivatives as immunotherapeutic agents, and IL-15-armored immune cells in adoptive cell therapy.

We also discuss the advantages and challenges of incorporating IL-15 in cell-based immunotherapy and provide directions for future investigation.

论文信息

作者
Zhou Y、Husman T、Cen X、Tsao T、Brown J、Bajpai A、Li M、Zhou K
单位
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.United States
文献类型
综述
期刊
International journal of molecular sciences2022 Jun 30
原文标识
PubMed 35806311 · DOI 10.3390/ijms23137311